I期临床-话题@MedSci

#I期临床#

570篇内容 | 7058人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652855, encodeId=a4e11652855af, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, objectType=article, longId=158471, objectId=e6371584e194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6371584e194, replyNumber=0, likeNumber=108, createdTime=2019-11-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6371584e194, moduleTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6371584e194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652904, encodeId=bf0916529045d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, objectType=article, longId=168391, objectId=bfb4168391a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfb4168391a4, replyNumber=0, likeNumber=59, createdTime=2019-11-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfb4168391a4, moduleTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfb4168391a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652862, encodeId=c7981652862b3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=85, createdTime=2019-03-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652903, encodeId=21d91652903b1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, objectType=article, longId=167971, objectId=033116e97107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=033116e97107, replyNumber=0, likeNumber=70, createdTime=2019-07-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=033116e97107, moduleTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=033116e97107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652893, encodeId=51f91652893e0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, objectType=article, longId=165928, objectId=8d7416592893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7416592893, replyNumber=0, likeNumber=69, createdTime=2019-05-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7416592893, moduleTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7416592893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652865, encodeId=d2a01652865ec, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=101, createdTime=2020-02-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652950, encodeId=7dbd165295053, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=67, createdTime=2020-08-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652929, encodeId=33931652929be, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验, objectType=article, longId=178212, objectId=d4f41e82121f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4f41e82121f, replyNumber=0, likeNumber=69, createdTime=2020-06-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4f41e82121f, moduleTitle=Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4f41e82121f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652884, encodeId=fc8116528841e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, objectType=article, longId=164216, objectId=25ad16421626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad16421626, replyNumber=0, likeNumber=51, createdTime=2019-06-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad16421626, moduleTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ad16421626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652920, encodeId=949a165292096, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, objectType=article, longId=176549, objectId=9a1f1e654908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1f1e654908, replyNumber=0, likeNumber=82, createdTime=2019-09-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1f1e654908, moduleTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1f1e654908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652845, encodeId=55871652845a5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=64, createdTime=2019-07-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652944, encodeId=37ea1652944f6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=69, createdTime=2019-11-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652868, encodeId=7e3816528687c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, objectType=article, longId=160548, objectId=fcad160548ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad160548ce, replyNumber=0, likeNumber=55, createdTime=2020-01-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad160548ce, moduleTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad160548ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652881, encodeId=9a0d1652881ad, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布, objectType=article, longId=162732, objectId=e5cb162e32cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5cb162e32cd, replyNumber=0, likeNumber=80, createdTime=2019-10-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5cb162e32cd, moduleTitle=逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5cb162e32cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, objectType=article, longId=180576, objectId=5f001805e6d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f001805e6d8, replyNumber=0, likeNumber=59, createdTime=2019-12-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f001805e6d8, moduleTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f001805e6d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652892, encodeId=438d16528923f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, objectType=article, longId=165920, objectId=671e16592080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=671e16592080, replyNumber=0, likeNumber=64, createdTime=2019-11-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=671e16592080, moduleTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=671e16592080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652900, encodeId=f5241652900eb, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019 ASCO ：Moderna宣布其mRNA个体化癌症疫苗I期临床研究的中期阳性数据, objectType=article, longId=167542, objectId=a91c16e54224, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91c16e54224, replyNumber=0, likeNumber=76, createdTime=2019-06-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91c16e54224, moduleTitle=2019 ASCO ：Moderna宣布其mRNA个体化癌症疫苗I期临床研究的中期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91c16e54224)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652844, encodeId=8e471652844e8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, objectType=article, longId=154956, objectId=189915495643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=189915495643, replyNumber=0, likeNumber=62, createdTime=2019-01-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=189915495643, moduleTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=189915495643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652860, encodeId=2fb4165286074, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=70, createdTime=2019-11-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652927, encodeId=9f73165292e6e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, objectType=article, longId=177982, objectId=e7881e798242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7881e798242, replyNumber=0, likeNumber=54, createdTime=2020-07-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7881e798242, moduleTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7881e798242)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验

2019-11-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者

2019-11-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-03-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人

2019-07-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

全球III期临床研究：roxadustat的心血管安全性得到证实

2019-05-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2020-02-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2020-08-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验

2020-06-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始

2019-06-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点

2019-09-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-07-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-11-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究

2020-01-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布

2019-10-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2019-12-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性

2019-11-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019 ASCO ：Moderna宣布其mRNA个体化癌症疫苗I期临床研究的中期阳性数据

2019-06-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗

2019-01-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-11-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用

2020-07-23

科室
- - 订阅+
  - 更多科室
工具
服务